Seems like some good numbers in this report but I don't get this:
Both these impacts contributed to a Net Operating Cash outflow of $568k
for the quarter. The delayed cash receipts were received early in July 2018 and will be recognised in the
September quarter
If the delayed payments were worth mentioning, they must be material, so why not include a dollar amount. Seems a bit amateur to me. Surely having a good grasp on cash flow is fundamental to valuing this company?
- Forums
- ASX - By Stock
- VIV
- Ann: Appendix 4C - Quarterly Report
Ann: Appendix 4C - Quarterly Report, page-2
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VIV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online